Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
40 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Surveal Pharma from Elsene, company number BE0837880555, closed financial year 2025 with a result of € 431,161 after tax. For that financial year Surveal Pharma recorded a gross margin of € 756,991 and equity of € 1.8 million. Compared with financial year 2024, the result moved from € -780,423 to € 431,161. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 1.8 million
▲ 31% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 431,161
▲ still € 780,423 loss in 2024
Profit after tax over the fiscal year.
€ 1.4 million
▼ 47% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.8 million.
People and assets in 2025
0.1
Average over the fiscal year, from the social balance sheet.
€ 2,124
▲ 269% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 4,427
▼ 94% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 633,171
▲ 72% vs 2024
€ 35,658 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 3 million
▼ 24% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,703
▼ 97% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 501,068 | € 805,497 | € 475,451 | € 756,991 | ▲ 59% |
| Profit after taxes | € 285,261 | € 542,414 | € -780,423 | € 431,161 | ▲ € 1.2 million |
| Equity | € 1,624,069 | € 2,166,482 | € 1,386,059 | € 1,817,220 | ▲ 31% |
| Total debts | € 5,264,078 | € 5,774,454 | € 4,533,273 | € 3,654,890 | ▼ 19% |
| Cash | € 2,850,206 | € 2,146,603 | € 2,717,630 | € 1,446,859 | ▼ 47% |
| Land & buildings | € 770,934 | € 495,674 | € 466,434 | € 437,193 | ▼ 6% |
| Retained profit | € 1,574,069 | € 2,116,482 | € 1,336,059 | € 1,767,220 | ▲ 32% |
| Bank debt | € 13,113 | € 400,000 | € 367,328 | € 633,171 | ▲ 72% |
| Balance sheet total | € 6,888,146 | € 7,940,936 | € 5,919,332 | € 5,472,110 | ▼ 8% |
| Employees (FTE) | - | 0.1 | 0 | 0.1 |
Key figures of Surveal Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Surveal Pharma?
What happened at Surveal Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 431,161. filed late Source: NBB ↗
- New establishment in Waterloo. KBO
- Sam Khoury became a director. NBB
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 285,261 profit in 2022 to € 431,161 profit in 2025.
Paid € 1.7 million in corporate taxes since 2022.
Best year ever: 2023, with € 542,414 profit.
A new publication or filing at Surveal Pharma? We notify you, reason included.
Follow Surveal PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Sam Khoury
Director
since 2018
Establishments
Establishment units
Physical locations of this company
Louizalaan 143 box 4
1050 Elsene
Avenue du Zodiaque 70
1410 Waterloo
Active since 6 July 2020
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 40 companies are registered at this address.
All companies at this address →Socobom
€ 123,176 gross margin · 2025
Comptoir Bogaerts
GEVELE
€ 3.7 million revenue · 2025
ELARMEC
€ 392,913 gross margin · 2025
AUSI A ET P
€ 6,839 gross margin · 2025
+35 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0837.880.555
- VAT number
- BE 0837.880.555
- Registered office
- Louizalaan 143 bus 4, 1050 Elsene
- Names & denominations
- Surveal Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 12 July 2011
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Vervaardiging van overige farmaceutische producten
Vervaardiging van geneesmiddelen
Vervaardiging van farmaceutische grondstoffen